Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the negative effects of anabolic androgenic steroids on various organ systems in men and reports no new results, highlighting the need for physician awareness.

This review discusses the unique healthcare needs and disparities faced by transgender individuals, highlighting the importance of cultural competency and skills in providers, but reports no new clinical findings.

This article discusses the clinical presentation and management challenges of menopausal acne, noting its multifactorial etiology and recommending tailored treatment approaches based on acne severity and associated features, without reporting new clinical results.

Finasteride helps improve hair growth in men with hair loss but may increase the risk of erectile dysfunction.

This review highlights the significant risks posed by mercury to the endocrine system, including disruptions in hormone synthesis and regulation, stress response, and potential reproductive dysfunction, while noting the need for further research on dose-response relationships and long-term impacts.

This review examines the sexual side effects of 5α-reductase inhibitors like finasteride, highlighting the increased risk of erectile dysfunction, libido reduction, and potential contribution to depression without new clinical findings.

In this study, the authors propose that drugs like trazodone and antipsychotics such as chlorpromazine, which can induce priapism, may help restore libido synaptic circuits, offering potential treatment for post-finasteride syndrome and post-SSRI sexual dysfunction.

This article reviews the challenges patients face after critical illness and highlights the potential benefits of individualized rehabilitation programs, though it reports no new clinical results.

Finasteride and dutasteride, used for prostate issues and hair loss, can cause side effects like sexual dysfunction and mental issues, which may continue even after stopping the medication, a condition called post-finasteride syndrome, for which there's currently no cure.

This article reviews the limited evidence on testosterone therapy for premenopausal women and notes a lack of long-term safety and effectiveness data for this population.

This case study reports that low-dose testosterone therapy improved libido and sexual functions in a 36-year-old fragile X carrier female with hypoactive sexual desire disorder when monitored regularly for lab parameters.

This review outlines the major health consequences of anabolic-androgenic steroid abuse, with a focus on sexual and reproductive issues, and suggests management prioritizes cessation and relapse prevention due to lack of robust randomized trials.

This review discusses post-finasteride syndrome, highlighting occasional adverse sexual and systemic effects in men and women, but reports no new research findings while emphasizing the need for better education about the drug's risks.

This study found that daily oral finasteride may increase hair count and improve hair appearance assessments in men with androgenetic alopecia, but it also appears to raise the risk of sexual dysfunction.

This review examines androgen replacement therapy in women for treating androgen deficiency symptoms and reports no new clinical results, while noting potential safety within a specific dose range.

This study found that longer exposure to 5α-reductase inhibitors significantly increased the risk of persistent erectile dysfunction, especially in younger men exposed to finasteride.

This study of FAERS data suggests that finasteride, particularly at the 1 mg dosage, is associated with a wide range of adverse effects not previously established in long-term studies, especially among younger men.

This review summarized existing research on finasteride and erectile dysfunction, finding a correlation between finasteride use for benign prostatic hyperplasia and ED, but not strongly for male androgenetic alopecia.

This review discusses sexual dysfunction as a side effect of α-blockers and 5-ARIs for BPH/LUTS, highlighting methodological flaws in existing studies and the need for more rigorous research.

This review suggests that while finasteride for male pattern hair loss was previously considered safe, there is now evidence associating 5-α reductase inhibitors with significant sexual and reproductive side effects.

This review identifies evidence of sexual adverse effects, particularly linked to finasteride, in men using systemic dermatologic medications but reports no new clinical findings.

This review discusses the known effects of medications for benign prostatic hyperplasia on sexual function and mechanisms of dysfunction but reports no new clinical results.

Finasteride for female hair loss has low side effects, more research needed.

This review discusses the efficacy and safety of oral finasteride for treating male pattern baldness and the potential persistent side effects, but no new results are reported.

Finasteride improves hair growth and satisfaction in men with male pattern baldness but may cause sexual side effects.

This article evaluated evidence on finasteride's effects on male reproductive health, finding contradictory data about its adverse effects, but consensus that such cases are infrequent in research and clinical settings.

In this review, researchers explored the potential of topical finasteride as an innovative treatment for male pattern hair loss, addressing the limitations of oral finasteride, such as side effects and inconsistent effectiveness.

This literature review reports prevalent sexual dysfunctions, notably vaginal dryness, in women undergoing endocrine therapy for hormone-dependent breast cancer, highlighting the need for more multidisciplinary research and care to improve patient well-being.

This article reviews treatment-induced sexual dysfunctions related to 5-alpha-reductase inhibitors and reports no new results; it highlights the need to better define and understand this controversial topic.

In this study, finasteride 1 mg demonstrated sustained efficacy over 10 years for men with androgenetic alopecia, especially in those over 30 or with higher AGA grades, with minimal side effects reported.